13665-88-8
13665-88-8
Chemical Structure
Mopidamol
Synonym(s): RA 233
- CAS No.: 13665-88-8
- Formula:C19H31N7O4
- Molecular Weight:421.49
IUPAC Name: 2,2',2'',2'''-((4-(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetrakis(ethan-1-ol)
InChIKey: FOYWNSCCNCUEPU-UHFFFAOYSA-N
SMILES: OCCN(C1=NC=C2C(C(N3CCCCC3)=NC(N(CCO)CCO)=N2)=N1)CCO
Biological Activity: Mopidamol (RA 233), a derivative of Dipyridamole (HY-B0312), is a phosphodiesterase inhibitor. Mopidamol can be used for non-small cell lung cancer (N-SCLC) research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mopidamol | Mopidamol (RA 233), a derivative of Dipyridamole (HY-B0312), is a phosphodiesterase inhibitor. Mopidamol can be used for non-small cell lung cancer (N-SCLC) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Eliasson R, Bygdeman S. Effect of dipyridamole and two pyrimido-pyrimidine derivatives on the kinetics of human platelet aggregation and on platelet adhesiveness. Scand J Clin Lab Invest. 1969 Sep;24(2):145-51. [Content Brief]
- [2]. Zacharski LR, et al. Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188. J Natl Cancer Inst. 1988 Mar 16;80(2):90-7. [Content Brief]
